Johnson & Johnson (JNJ) is a current holding within the US Starter Pack.
Johnson & Johnson reported second quarter results before the open on Wednesday 15 July. Adjusted earnings per share of $2.90 beat the $2.86 consensus, and revenue of $25.3 billion, up 6.6 percent year on year, cleared estimates near $25.0 billion. GAAP EPS was $2.27.
Innovative Medicine grew 7.8 percent to $16.4 billion, or 6.8 percent on an operational basis. Tremfya posted its first $2 billion quarter, up 72.5 percent and well ahead of the $1.74 billion analysts expected, with Darzalex, Carvykti, Tecvayli, Rybrevant with Lazcluze, Spravato and Caplyta also contributing. MedTech grew 4.5 percent reported and 5.4 percent operationally to $8.9 billion, and supplied the quarter’s soft spot: cardiovascular sales fell about 2 percent.
Management raised full-year guidance. Reported sales guidance moved to $100.8 to 101.4 billion, a midpoint of $101.1 billion and 7.3 percent growth, keeping the company on track for its first year above $100 billion in revenue. Adjusted EPS guidance rose 13 cents to a midpoint around $11.68, an 8.2 percent increase on 2025. CEO Joaquin Duato said: “We said 2026 would be a year of accelerated growth and impact for Johnson & Johnson, and with our Q2 beat on the top and bottom line and raised guidance, we are delivering.”
The stock slipped about 1.5 percent on the day, with the MedTech and cardiovascular softness attracting more attention than the raised outlook; it recovered around 3.5 percent over the following week. The quarter leaves the pharmaceutical business carrying the growth case, Tremfya scaling faster than forecast, and the guidance implying a stronger second half.
